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ABSTRACT 
In HIV/HCV co-infected patients, the accelerated severity of liver disease, associated 
comorbidities, and mortality on the waiting list could change the possibility and results of liver 
transplantation (LT). Intention-to-treat survival analysis (ITTA) can accurately estimate the 
applicability and efficacy of LT. The primary objective of this study was to compare the 
survival of patients with HCV with and without HIV infection. We analysed a cohort of 199 
patients with HCV infection enrolled for LT between 1998 and 2015; 17 were also infected with 
HIV. The patients with HCV/HIV co-infection had higher mortality on the waiting list than 
those with HCV monoinfection (35.3% vs. 4.6%; P<0.001). ITTA at 1, 3, and 5 years was 75%, 
64%, and 57% for HCV monoinfection and 52%, 47%, and 39% for HCV/HIV co-infection, 
respectively (Wilcoxon test P<0.05). The ITTA at 1, 3, 6, and 12 months and was 96%, 91%, 
87%, and 75% for HCV monoinfection and 76%, 70%, 64%, and 52% for HCV/HIV co-
infection, respectively (Logrank P<0.05, Wilcoxon test P<0.01). A Cox regression analysis was 
carried out including all variables with predictive value in the univariate analysis, showing that 
only donor age > 70 years (HR = 3.12, P<0.05), UNOS 1 status (HR = 10.1, P<0.01), MELD 
(HR = 1.13, P<0.001), and HIV co-infection (HR = 2.65, P<0.05) had independent negative 
predictive value for survival. Conclusion Our study indicates that HIV co-infection is a factor 
in mortality prior to transplantation and associated with higher mortality on the waiting list.     
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INTRODUCTION 
According to the Spanish Liver Transplant Registry, 36% of orthotopic liver transplants 
(OLT) carried out in our country correspond to patients infected with hepatitis C virus 
(HCV) (1). In these patients, the infection can be associated with different comorbidities, 
including hepatocellular carcinoma (HCC), co-infection with hepatitis B virus (HBV), and 
co-infection with human immunodeficiency virus (HIV), among others.     
Until a few years ago, HIV infection was an absolute contraindication for any type of 
transplant due to the vital prognosis of these patients and the fear that transplant-associated 
immunosuppression could accelerate the progression of the disease or increase the risk of 
opportunistic infections. Since the introduction of highly active combined antiretroviral 
treatment (cART) (1) in 1996, the situation of HIV-infected patients has changed radically, 
with dramatically reduced morbidity due to opportunistic processes and reduced overall 
mortality of patients with AIDS (2). This, in turn, has resulted in sufficient time for chronic 
processes to evolve to terminal failure (hepatic, renal, cardiac), the only possible approach 
for which is transplantation (3). 
The Spanish OLT in HIV-Infected Patients Working Group has published several papers 
with transplant results and associated prognostic factors in HCV/HIV co-infected liver 
transplant recipients (4,5). However, these works do not consider that the accelerated 
severity of hepatopathy, associated comorbidities, and mortality on the waiting list can 
change the possibility and results of treating patients. Therefore, in these situations, 
intention-to-treat survival analysis (ITTA) can accurately estimate the applicability and 
efficacy of liver transplantation. The primary objective of this study was to compare the 
intention-to-treat survival of patients with advanced hepatopathy caused by HCV 
monoinfection and HCV/HIV co-infection.     
PATIENTS and METHODS 
 Patients and study design 
This is a retrospective study using a prospectively collected database. All patients HCV-
positive and enlisted for primary non-paediatric orthotopic liver transplantation (OLT) after 
2004 (starting date of the HIV-HCV co-infected LT programme) were included in the study 
(N=199). The design of the study is shown in Figure 1. The monitoring start date was the 
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date when the patient was included on the waiting list. The main variable of the study was 
the intention-to-treat survival; thus, the death of the patient was considered to be the event. 
The patients were monitored by the electronic Health Record of the Regional Community of 
Aragon and of the hospital itself until they died, censoring the last documented day when 
they were alive. The basal characteristics, evolution on the waiting list, reasons for 
exclusion from the list, and their subsequent evolution were analysed for each patient.     
 Transplant criteria 
HIV-infected patients had to fulfil the following criteria according to their infection status 
(6): no AIDS-defining events except tuberculosis, oesophageal candidiasis, or Pneumocystis 
jiroveci pneumonia; CD4 T cell count >100 cells/µL; and an undetectable plasma HIV-
RNA viral load (or suppressible with cART). Former intravenous drug users had to have 
abstained from heroin or cocaine use for more than 2 years. The minimum period of 
abstinence for alcohol was 6 months.  
In regards to liver disease, the criteria for accepting HIV-infected patients for 
transplantation were the same as those followed in Spain for HIV-negative patients: a 
minimum Child-Turcotte-Pugh score of 7 for patients with cirrhosis, and one tumour <5 cm 
or two to three tumours <3 cm in the absence of hepatic macrovascular tumour invasion and 
extrahepatic metastases in patients with HCC. 
 Donor procurement and characteristics 
All donors were brain death donors. Donor liver recovery was performed using 
conventional multiorgan procurement techniques. The aorta and portal vein were perfused 
with preservation solution cooled to 4ºC by gravity in situ and on the back table through the 
portal vein. University of Wisconsin solution and Celsior solution were used 
indiscriminately. Total perfusion volumes were 4, 2, and 1 L for Celsior solution and 3, 2, 
and 1 L for University of Wisconsin solution. After recovery, the grafts were kept in 
conventional bags containing the same solution at 4ºC until transplantation. 
The following donor variables were analysed and compared in both groups: age, sex, cause 
of death, number of days in the ICU, donor allocation, and graft steatosis. The donor risk 
index, a score derived from donor variables that helps estimate the influence of donor 
characteristics on the patient and graft outcome after transplantation, was also calculated 
according to the criteria described by Feng et al. (7). 
 Technical aspects 
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OLT was performed with preservation of the retrohepatic vena cava (piggyback technique) 
and without veno-venous bypass. The graft was washed systematically before reperfusion of 
the portal vein with 1200 mL of cold Ringers lactate. An arterial anastomosis was carried 
out between the graft celiac trunk or its branches and the common recipient hepatic artery or 
its branches. Protocol wedge liver biopsies were obtained prior to graft perfusion, during 
procurement, and immediately before closing the recipient laparotomy. The standard 
technique for biliary anastomosis was choledocho–choledocho anastomosis. Split liver 
transplantations were not performed in this population. 
 Post-transplant management 
Induction immunosuppression consisted of standard dual therapy with cyclosporine or 
tacrolimus and steroids. Some patients received monoclonal antibodies (basiliximab), and 
some patients with impaired renal function received mycophenolate mofetil. 
Cytomegalovirus (CMV) prophylaxis with gancyclovir was given in the following 
circumstances: positive donor status and negative recipient, retransplantation, or the use of 
monoclonal antibodies. 
cART was administered until the day of surgery and resumed when the patient was stable 
and oral intake reintroduced. Antiretroviral drugs were administered according to national 
guidelines (8). HIV-infected recipients received the same immunosuppressive regimens as 
HIV-negative patients according to local protocols.  
 Diagnosis, strategies, and protocols 
The definitions of HIV, HCV, and HBV infection and AIDS-defining events were based on 
standard criteria (9). Strategies for local prioritisation were based on model of end-stage 
liver disease (MELD) allocation. Patients on the waiting list were monitored and treated 
every 2-3 months or earlier depending on their clinical situation. Patients with HCC and 
lesions > 3 cm or multinodularity underwent radiofrequency (RF) and/or 
chemoembolisation (TACE) while on the waiting list depending on individual 
characteristics. Patients could be removed from the list due to repeated improvement. 
Diagnosis of acute rejection was always based on histopathological features following the 
Banff schema (10). Doppler ultrasonography was performed within the first 48 hours after 
liver transplantation and in the 7 to 10 days following transplantation. If the findings were 
equivocal or indicated that an abnormality may be present, an angiographic study was 
prescribed. The severity of recurrent hepatitis C was routinely determined using the Scheuer 
index (11) at the end of the first year after liver transplantation. 
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 Study endpoints 
The monitoring start date was the date when the patient was included on the waiting list. 
The primary endpoint of the study was the overall survival from the time of listing (ITTA, 
including dropouts), and the patient’s death was considered to be the event. The secondary 
endpoint was overall survival after transplantation (including only liver transplant 
recipients). 
 Statistical analysis 
The HCV monoinfection and HCV/HIV co-infection groups were compared according to 
patient characteristics, evolution on the waiting list, operative and postoperative outcomes, 
and long-term outcomes. Continuous variables were compared using the Student t-test and 
categorical variables using the chi-square test for associations. Continuous variables are 
presented as the mean and standard deviation.  
Overall survival was calculated using the Kaplan-Meier method; differences between 
subgroups were compared using the log-rank test and Wilcoxon test. To identify predictors 
of mortality, a multivariate Cox proportional hazards model was performed. Significant 
variables in a univariate analysis were included in a multivariate analysis.  
Significance was defined as a P value < 0.05. All statistical analyses were performed in 
IBM

 SPSS

 Statistics version 22.0 (
©
Copyright IBM Corporation 1989 to 2013, Chicago, 
IL, USA). 
RESULTS 
Patient characteristics 
From the launch of our liver transplant programme in December 1998 to June 2015, a total 
of 567 patients were included for primary OLT, including 199 with HCV infection that 
were included in this study. The characteristics of these patients are presented in Table 1. 
The subgroup of patients with HCV/HIV co-infection included on the waiting list (since 
2004) were compared to the patients with HCV monoinfection who were on the list (ratio 
1:10.7) and the patients with HCV monoinfection who were included in the same time 
period (ratio 1:7.6). 
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Of all analysed variables, a lower average age (45.6 years vs. 55.0 or 54.9 years; P<0.001) 
and a different distribution of HCV genotypes (P<0.01) were recorded in the group of 
patients with HCV/HIV co-infection. The other variables showed no significant differences.  
Evolution on the waiting list 
The evolution of the patients on the list included in the study is presented in Table 2. First, 
the patients with HCV/HIV co-infection had higher mortality on the waiting list than HCV 
monoinfection patients (35.3% vs. 4.9% or 4.6%, respectively; P<0.001), so the percentage 
of transplant recipients was lower among patients with HCV-HIV co-infection (52.9% vs. 
83.5% or 82.3%; P<0.01). Regarding mortality on the waiting list, the patients on the list 
who died, did so in less time on average than the transplanted patients on the list. The 
causes of death of co-infected patients were liver disease decompensation (n=2), 
spontaneous bacterial peritonitis (n=2), urinary origin sepsis (n=1), and respiratory distress 
syndrome after pneumonia (n=1). 
No significant differences were recorded regarding the number of patients excluded from 
the list and the reasons for exclusion. The most common cause was contraindication 
because of HCC progression. The overall mortality according to ITTA was higher in the 
group with HCV/HIV co-infection than HCV monoinfection patients (58.8% vs. 44.5% or 
36.2%, respectively), but there were no significant differences between the groups.     
 Characteristics and outcomes of transplantation 
The characteristics of the transplants carried out and their outcomes are presented in Tables 3 
and 4. The group with HCV/HIV co-infection was compared only to the total HCV 
monoinfection group. No differences were detected among the donors in any of the variables 
studied or in the case of peritransplant variables concerning surgery and the donor-recipient 
correlation (Table 3). A higher percentage of retransplantation was found among patients 
with HCV/HIV co-infection than patients with HCV monoinfection (33.3% vs. 11.2%). 
However, the overall mortality was lower among the patients with co-infection (33.3% vs. 
44.1%). Neither of these two variables reached significance.  
In the group with HCV monoinfection, one-third of the patients who died did so because of 
graft dysfunction, and 9 of them died on the waiting list for retransplantation. In the co-
infected group, two patients died because of graft HCV reinfection and one because of 
pneumonia with sepsis and multiorgan failure. 
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The post-transplantation Kaplan-Meier survival curves for the HCV monoinfected and 
HCV/HIV co-infected patients, regarding both the patient and the graft, indicated no 
significant differences in these groups. The graft survival was 74% vs. 66% at 1 year, 62% 
vs. 55% at 3 years, and 53% vs. 44% at 5 years. The patient survival was 78% vs. 88% at 1 
year, 68% vs. 77% at 3 years, and 59% vs. 64% at 5 years.     
 Intention-to-treat survival analysis 
Regarding the ITTA, Figure 2 presents the global survival curve. The survival at 1, 3, and 5 
years was 75%, 64%, and 57% for patients with HCV monoinfection and 52%, 47%, and 
39% for patients with HCV/HIV co-infection, respectively. The mortality in the group of 
patients with HCV/HIV co-infection was significantly higher (Wilcoxon test P<0.05) in the 
first few months and stabilised after a year. Therefore, we divided the survival curve into 
two parts: short-term (less than 1 year) and long-term (more than 1 year). The curve for 
short-term survival (Figure 3) clearly indicated a significantly higher mortality (Logrank 
P<0.05, Wilcoxon test P<0.01) in the group of patients with HCV/HIV co-infection. This 
rate was more accentuated in the first few months and stabilised after the third month. The 
survival at 1, 3, 6, and 12 months was 96%, 91%, 87%, and 75% for patients with HCV 
monoinfection and 76%, 70%, 64%, and 52% for patients with HCV/HIV co-infection, 
respectively.     
 COX regression analysis 
A proportional Cox regression analysis was carried out in order to identify predictors of 
short-term survival (<1 year) in patients with HCV infection. All variables related to donor 
and recipient, represented in Tables 1 and 3, were included in the univariate analysis. The 
significant variables were then included in the multivariate analysis (Table 5). Of all the 
parameters analysed, only donor age > 70 years (HR = 2.51, P<0.05), UNOS 1 status (HR = 
8.93, P<0.001) and UNOS 2 status (HR = 3.65, P<0.05), MELD (HR = 1.12, P<0.001), and 
HIV co-infection (HR = 2.95, P<0.01) had a negative predictive value for survival, whereas 
less time on the waiting list (HR = 0.98, P<0.05), isosexuality between donor and recipient 
(HR = 0.39, P<0.05), and donor normonatremia (HR = 0.96, P<0.05) had a positive 
predictive value (Table 5). Of all the variables with predictive value in the univariate 
analysis, only donor age > 70 years (HR = 3.12, P<0.05), UNOS 1 status (HR = 10.1, 
P<0.01), MELD (HR = 1.13, P<0.001), and HIV co-infection (HR = 2.65, P<0.05) had an 
independent negative predictive value for survival (Table 5).  
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DISCUSSION 
Several studies have concluded that OLT is an effective procedure in HCV/HIV co-infected 
liver recipients with short-term survival similar to that observed in patients with HCV 
monoinfection and lower but acceptable long-term survival (12,13). In HCV/HIV co-
infected liver transplant candidates the problem gets worse long before the transplantation, 
as life expectancy is shorter after liver disease becomes decompensated than in patients who 
are not infected (14,15). In one study, patients infected with HIV and suffering from an end-
stage liver disease Child-Pugh A had an average survival of 26 months; if the patient was at 
the stage of advanced Child-Pugh (B or C) survival was 10 and 14 months, respectively 
(14). Another study detected very low survival in patients infected with HIV after the first 
episode of hepatic decompensation (15).  
Pineda et al. (16) have shown that the evolution of cirrhosis after the first decompensation 
in patients co-infected with HIV and HCV is much worse than in HCV monoinfected 
patients; survival was 54% vs. 74% at 1 year, 40% vs. 61% at 2 years, and 25% vs. 44% at 
5 years, respectively. Other groups have reported similar data (17,18). On the other hand, 
patients co-infected with HCV and HIV have lower access to liver transplantation compared 
to patients with HCV monoinfection (14,19). Moreover, Subramanian et al. (19) reported a 
higher mortality rate (14.4% vs. 10.5%, P>0.05) for co-infected patients on the waiting list 
compared to monoinfected patients. In addition, a significantly lower proportion of HIV-
positive transplant candidates than HIV-negative patients underwent liver transplantation 
during the study period.  
In this group of patients, ITTA allows transplantation to be considered not only a 
complicated surgery, but also a complex process that involves a sequence of different 
procedures (i.e., patient selection, evolution on the waiting list, allocation of organs, 
transplant results), more accurately estimating the applicability and efficacy of liver 
transplantation in these patients. A Spanish multicentre study (4) indicated the need for 
intention-to-treat analysis, which could not be carried out because of a lack of information 
on patients who did not receive a transplant.  
Vibert et al. (21) published an ITTA of liver transplantation in HCC patients, analysing the 
impact of HIV infection. They found a higher dropout rate among HIV patients and 
worsened results of liver transplantation for HCC on an intent-to-treat basis. To the best of 
our knowledge, our study is the first to perform an ITTA in HCV/HIV co-infected liver 
recipients. Patients with HCV/HIV co-infection had significant differences from patients 
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with HCV monoinfection; the age of the former was significantly lower and genotype 1 
more prevalent in the group of patients with monoinfection. These events were also 
recorded in the Spanish multicentre study (4). This genotype is associated with higher HCV 
recurrence after transplantation and higher incidence of evolution to fibrosis and cirrhosis 
(22).  
The evolution on the waiting list is not widely discussed in the literature. Our analysis 
showed that mortality on the waiting list was clearly higher in the HCV/HIV co-infected 
patients (35.3% vs. 4.6%; P<0.001). Importantly, this mortality was not associated with a 
longer permanence on the list. In 2013 in Spain, according to the report of the National 
Transplant Organisation (23), mortality of adults on the waiting list for liver transplantation 
was 5.5%; there are no data for different pathologies. The only communication we found on 
ITTA made no reference to mortality on the list but indicated that the percentage of patients 
on the list who were excluded or died was significantly higher in the group with HCV/HIV 
co-infection (53% vs. 6%) (24).  
In regards to the post-transplantation results, though the differences were not significant, the 
group of co-infected patients had a higher rate of graft loss because of HCV reinfection than 
monoinfected patients (22.2% vs. 11.2%). These data were also confirmed by other authors 
who relate the graft loss to the need for further immunosuppression in these patients, which 
results in premature HCV reactivation and faster evolution to fibrosis (12,13). In the study 
carried out by Miro et al. (4), the short-term post-transplant survival was similar, but after 5 
years it was significantly worse, though acceptable. In our study, the overall post-transplant 
survival was similar in both groups.     
The short-term ITTA indicated higher mortality in the first few months, which was related 
to higher mortality on the waiting list for the group of patients with HCV/HIV co-infection 
and stabilised after the third month. In the only communication on an ITTA in patients with 
HCV/HIV co-infection mentioned above (24), the probability of survival in these patients 
was significantly lower than the rest (0.68, 0.45, and 0.30 vs. 0.91, 0.85, and 0.79 at 6, 12, 
and 24 months, respectively).  
Finally, with respect to the prognostic factors for short-term survival (<1 year) in patients 
with HCV infection, donor age > 70 years, UNOS status 1 and 2, MELD, and HIV co-
infection had a negative predictive value, whereas less time on the list, isosexuality between 
donor and recipient, and donor normonatremia had positive predictive value. Of all the 
variables with predictive value in the univariate analysis, only donor age > 70 years, UNOS 
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status 1, MELD, and HIV co-infection had an independent negative predictive value for 
survival. HIV co-infection has been reported to be an independent factor for mortality after 
transplantation in patients with HCV infection (4). Our study indicates that, in addition to 
being a risk factor after transplantation, HIC co-infection is also a factor for mortality prior 
to transplantation and associated with higher mortality on the waiting list.  
With regard to donor age, this factor is becoming increasingly well known to affect graft 
survival, along with many other factors. The age cut-offs proposed in the literature range 
from 50 to 70 years. We found significant differences in patients >70 years old. Notably, 
the larger the sample size the higher the probability of finding the differences caused by the 
age factor and the cut-off probably lower. Our sample is small and may only detect cases in 
which age plays an important role, coinciding with a higher cut-off. 
The main limitation of our study is the small number of HCV/HIV co-infected patients. 
Therefore, more prospective studies are needed to confirm these observations and more 
accurately determine the risk factors and need for pre-transplant assessment and different 
policies in this group of patients.  
In conclusion, liver transplantation is a possible treatment for patients with HCV/HIV co-
infection and end-stage liver disease, but these patients have lower short-term survival (less 
than 1 year), mainly related to higher mortality on the waiting list. Receptor-dependent 
factors with worse independent predictive value for short-term survival in patients with 
HCV infection were: UNOS 1 status at enrolment on the list, MELD, and HIV co-infection.  
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FIGURE LEGENDS
Figure 1. Flowchart describing the patients included in the study. 
Figure 2. Global Survival by Intention-to-treat analysis for HCV monoinfection compared to 
HCV/HIV co- infection. 
Figure 3.  Short-term survival (< 1 year) by Intention-to-treat analysis for HCV monoinfection 
compared to HCV/HIV co-infection. 
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Table 1. Main Characteristics of the Cohort 
All cases 
HCV 
Monoinfection 
HCV/HIV 
Coinfection PValue* 
All cases Since 2004 Since 2004 
N 199 182 130 17 
Age (years)
1
54.2 + 8.7 55.0 + 8.6 54.9 + 8.6 45.6 + 3.2 < 0.001 
Sex: Male (vs female)
2
 153 (76.9) 139 (76.4) 103 (79.2) 14 (82.4) 0.95 
Blood Type
2
: 0.42 
O 83 (41.7) 77 (43.3) 58 (44.6) 6 (35.2) 
A 92 (46.2) 84 (46.2) 54 (41.5) 8 (47.0) 
B 18 (9.0) 15 (8.2) 14 (10.7) 3 (17.6) 
AB 6 (3.1) 6 (3.3) 4 (3.0) - 
MELD score
1
 15.5 + 5.8 15.2 + 5.2 15.2 + 5.2 17.9 + 9.6 0.63 
Child-Pugh class
2
0.29 
A 43 (21.6) 38 (20.3) 32 (24.4) 5 (31.2) 
B 77 (38.7) 74 (41.2) 50 (38.5) 3 (12.5) 
C  79 (39.7) 70 (38.3) 48 (37.0) 9 (56.2) 
UNOS status
2
 0.08 
ICU admission 13 (6.6) 10 (5.6) 6 (4.4) 3 (15.3) 
Hospital admission 34 (17.1) 29 (15.6) 19 (15.0) 5 (30.7) 
With continuous care 98 (49.2) 90 (49.3) 59 (45.1) 8 (46.1) 
At home 54 (27.1) 53 (29.3) 46 (35.3) 1 (7.6) 
Comorbidities: 
Ex-alcholism
2
 28 (14.1) 27 (14.8) 17 (13.1) 1 (5.9) 0.36 
HCC
2 
68 (34.2) 64 (35.2) 50 (38.5) 4 (23.5) 0.48 
Number of Nodules
2
0.67 
1 nodule<3 cm 20 (29.4) 20 (31.3) 16 (32.0) - 
1 nodule>3 cm 19 (27.9) 17 (26.5) 14 (28.0) 2 (50) 
Multinodular 29 (42.7) 27 (42.2) 20 (40.0) 2 (50) 
Tumour diameter
1
0.23 
1 nodule 33.4 + 12.2 32.6 + 12.2 32.0 + 11.9 44.5 + 7.7 
Multinodular(max) 25.0 + 4.9 25.7 + 4.9 26.3 + 4.7 30.0 + 0 
Treatment prior to OLT
2
0.82 
TACE 12 (70.6) 11 (73.3) 11 (73.3) 1 (50.0) 
RFA 4 (23.5) 3 (20.0) 3 (20.0) 1 (50.0) 
TACE and RFA 1 (5.9) 1 (6.7) 1 (6.7) - 
HBV coinfection
2
3 (1.5) 2 (1.1) 1 (0.8) 1 (5.9) 0.06 
HCV Infection: 
HCV Genotype
2
 < 0.01 
1 149 (74.9) 141 (77.5) 104 (80.0) 8 (47.1) 
2 1 (0.5) - - 1 (5.9) 
3 21 (10.6) 18 (9.9) 17 (13.0) 3 (17.6) 
4 11 (5.5) 7 (3.8) 5 (3.9) 4 (23.5) 
Others 17 (8.5) 16 (8.8) 4 (3.1) 1 (5.9) 
Plasma HCV RNA viral 
load (UE
6
/mL)
1 9.9 + 3.8 9.8 + 4.4 9.8 + 4.4 10.5 + 17.9 0.49 
Negative plasma HCV 
RNA viral load before LT
2 10 (5.0) 9 (4.9) 7 (5.4) 0 NA 
HIV Infection**: 
CD4
+
 Cell count
1
220 + 164 NA 
CD8
+
  Cell count
1
369 + 280 NA 
CD4 / CD8
1
 0.57 + 0.13 NA 
Plasma HIV RNA viral load 
< 200 copies/mL
2 10 (58.8) NA 
Type of cART
2
 NA 
NRTI based 5 (29.4) 
NNRTI based 5 (29.4) 
PI based 7 (41.2) 
HCV Hepatitis C Virus; HIV Hepatitis Inmunodeficiency Virus; MELD Model for End-stage Liver Disease; UNOS United Network for 
Organ Sharing; HCC Hepatocellular Carcinoma; TACE Transarterial Chemoembolisation; RFA Radiofrequency Ablation; HBV 
Hepatitis B Virus; cART combined Antiretroviral Treatment; NRTI Nucleoside Reverse Transcriptase Inhibitor; NNRTI Non 
Nucleoside Reverse Transcriptase Inhibitor; PI Protease Inhibitor. 
1 
The data are presented as mean and standard deviation. 
2 
The data are presented as n (%). 
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* P-value. HCV/HIV Coinfection versus HCV Monoinfection (the same for both groups); NA: not applicable.
** HIV infection (data at listing): Absolute number (cells/µL), Patient Plasma HIV-RNA below 200 copies/mL. 
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Table 2. Intention-to-treat evolution of the patients included in the study 
All cases 
HCV 
Monoinfection 
HCV/HIV 
Coinfection PValue* 
All cases Since 2004 Since 2004 
N 199 182 130 17 
Dropped on list
2
 14 (7.0) 12 (6.6) 8 (6.2) 2 (11.8) 0.09 
Time at list
1
122.0 + 78.3 117.0 + 80.5 104.3 + 42.8 152.0 + 79.1 0.82 
Causes to drop out
2
0.46 
Contraindication 8 (57.1) 7 (58.3) 5 (62.5) 1 (50) 
Time at list
1
 78.8 + 38.4 76.4 + 40.8 88.0 + 29.0 96 NA 
Improvement 6 (42.9) 5 (41.7) 3 (37.5) 1 (50) 
Time at list
1
 179.5 + 83.3 173.8 + 91.9 152.7 + 53.2 208 NA 
Evolution
2
0.43 
Death 6 (42.9) 5 (41.7) 3 (37.5) 1 (50) 
Alive 8 (57.1) 7 (58.3) 5 (62.5) 1 (50) 
Dead on waiting list
2
15 (7.5) 9 (4.9) 6 (4.6) 6 (35.3) < 0.001 
Time at list
1
30.4 + 27.1 31.0 + 7.4 36.6 + 10.4 29.5 + 14.5 0.91 
Causes of dead
2
0.06 
Liver Complications 9 (60.0) 7 (77.7) 5 (83.3) 2 (33.3) 
Infections 5 (33.3) 2 (22.2) 1 (16.6) 3 (50.0) 
Others 1 (6.66) - - 1 (16.6) 
LT
2
161 (80.9) 152 (83.5) 107 (82.3) 9 (52.9) < 0.01 
Time at list
1
72.9 + 74.2 72.7 + 74.2 92.5 + 80.1 74.8 + 65.5 0.53 
Evolution
2
0.93 
Death 71 (44.1) 68 (44.7) 39 (36.4) 3 (33.3) 
Alive 90 (55.9) 84 (55.3) 68 (63.6) 6 (66.7) 
Global ITTA
2
0.07 
Dead 91 (45.7) 81 (44.5) 47 (36.2) 10 (58.8) 
Alive** 108 (54.3) 101 (55.5) 83 (63.8) 7 (41.2) 
HCV Hepatitis C Virus; HIV Hepatitis Inmunodeficiency Virus; LT Liver Transplantation; ITTA Intention-To-Treat Survival Analysis. 
1
The data are presented as mean and standard deviation. 
2
The data are presented as n (%). 
* P-value. HCV/HIV Coinfection versus HCV Monoinfection (the same for both groups); NS not significant; NA: not applicable.
** Included 9 HCV Monoinfection Patients on Waiting list for OLT 
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Table 3. Characteristics of liver transplants 
All cases 
HCV 
Monoinfection 
HCV/HIV 
Coinfection 
P 
Value* 
N 161 152 9 
Matching Donor Variables: 
Age (years)
1
49.4 + 16.9 (11-82) 49.4 + 17.1 (11-82) 48.3 + 13.3 (28-71) 0.73 
Sex Male (vs female)
2
 98 (60.9) 95 (62.5) 3 (33.3) 0.06 
Days in ICU
1
 2.9 + 2.1 (1-16) 2.9 + 2.4 (1-16) 2.3 + 3.6 (1-14) 0.82 
Cause of donor brain death
2
0.49 
CVA 103 (64.0) 97 (63.9) 6 (66.7) 
Head Trauma 42 (26.1) 41 (26.9) 1 (11.1) 
Others 16 (9.9) 14 (9.2) 2 (22.2) 
Donor Allocation
2
 0.08 
Local 112 (69.6) 107 (70.4) 5 (55.6) 
Regional 5 (3.1) 5 (3.3) - 
National 44 (27.3) 40 (26.3) 4 (44.4) 
Steatosis
2
Mild < 30  15 (9.9) 14 (9.2) 1 (11.1) 0.61 
Donor Risk Index: 0.71 
Median 1.48 1.48 1.52 
Interquartile range 1.24 – 1.76 1.24 – 1.76 1.26 – 1.78 
Matching Recipient Variables: 
Age (years)
1
55 + 8 (35-68) 55 + 8 (35-68) 46 + 3 (41-51) < 0.01 
Sex Male(vs female)
2
 125 (77.6) 117 (76.9) 8 (88.9) 0.52 
HCC
2
 56 (34.8) 53 (34.9) 3 (33.3) 0.67 
Peritransplant Variables: 
Elective (vs urgent)
2
 158 (98.1) 149 (98.0) 9 (100) 0.89 
Correlation (donor vs recipient)
2
 
Blood Type 0.74 
Isogroup 159 (98.8) 150 (98.7) 9 (100) 
Compatible 2 (1.2) 2 (1.3) - 
Isosexuality 92 (57.1) 88 (57.9) 4 (44.4) 0.62 
Technique: 
Preservation solution (UW)
2
 97 (60.2) 91 (59.9) 6 (66.7) 0.34 
Cold ischemia time
1
 (min) 375 + 114 (188-720) 374 + 115 (188-720) 397 + 94 (310-515) 0.65 
Surgery time
1
 (min) 325 + 64 (180-520) 324 + 63 (180-520) 354 + 93 (205-620) 0.37 
Intraoperative infusion of blood 
products: 
RBCs
1
 (units) 4.1 + 3.9 (0-20) 4.1 + 3.9 (0-20) 4.5 + 4.0 (1-10) 0.98 
FFP
1
 (units) 4.1 + 3.1 (0-15) 4.1 + 3.1 (0-15) 2.5 + 2.1 (1-4) 0.12 
Platelets
1
 (Nº pool) 1.7 + 2.3 (0-10) 1.1 + 2.3 (0-10) - NA 
Intraoperative Events 
S. Postreperfusion
2
23 (14.3) 22 (14.5) 1 (11.1) 0.52 
Intraoperative mortality 0 0 0 NA 
HCV Hepatitis C Virus; HIV Hepatitis Inmunodeficiency Virus; ICU Intensive Care Unit; CVA Cerebrovascular Accident;; UW 
University of Wisconsin; RBCs red blood cells; FFP fresh frozen plasma;  
Allocation: Local in the city; Regional <200 km; National >200 km. 
1
The data are presented as mean and standard deviation (range). 
2
The data are presented as n (%).
* P-value. HCV/HIV Coinfection versus HCV Monoinfection (the same for both groups); NA: not applicable.
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Table 4. Results of liver transplants 
HCV 
Monoinfection 
HCV/HIV 
Coinfection 
P Value* 
N 152 9 
Posttransplant variables: 
Primary dysfunction
3
1 0 NA 
Complications
3
: 
Acute Rejection 15 0 NA 
Vascular 2 2 0.53 
Biliary 8 1 0.72 
cART and HIV-1 viral load: 
Time to re-start
1
(days) 9 (5-20) NA 
Type
3
NA 
NRTI-based 2 
NNRTI-based 3 
PI-based 4 
Undetectable HIV viral load
3
8 NA 
Days in ICU
1
 5 (4-8) 5 (4-6) 0.58 
Days on floor
1
13 (10-17) 10 (9-18) 0.73 
Days in hospital/total
1
18 (15-23) 18 (13-22) 0.41 
Retransplant
2
: 17 (11.2) 3 (33.3) 0.06 
Reasons
3
: NA 
Primary dysfunction 1 0 
Liver recurrence 8 0
b
Chronic rejection 3 0 
Vascular complications 0 2 
Biliary complications 5 1 
Kaplan-Meier Graft Survival
4
: 0.63 
At 1 year 74 (67-81) 66 (36-88) 
At 3 years 62 (53-70) 55 (23-81) 
At 5 years 53 (44-62) 44 (13-72) 
Patient Survival: 
Monitoring period(days): 0.71 
Mean + Standard deviation 1804 + 1687 1878 + 1224 
Range 10 - 6042 279 - 3996 
Median 1272 1194 
Interquartile range 302 - 4507 1110 - 2861 
Global Death
2
 67 (44.1) 3 (33.3) 0.16 
FunctionGraft
3
0.35 
DDG 23 a 2
b
DFG 44 1 
Kaplan-Meier Patient Survival
4
: 0.47 
At 1 year 78 (71-84) 88 (64-98) 
At 3 years 68 (60-76) 77 (45-94) 
At 5 years 59 (50-68) 64 (32-87) 
HCV Hepatitis C Virus; HIV Hepatitis Inmunodeficiency Virus;; ICU Intensive Care Unit; DDG Died with Disfunctioning Graft; DFG 
Died with Functioning Graft. 
1
The data are presented as median (Interquartile Range). 
2
The data are presented as n (%),
3
The data are presented as n. 
4
The data
are presented as % (95% CI) 
* P-value. HCV/HIV Coinfection versus HCV Monoinfection (the same for both groups); NA: not applicable.
a 
9 patients died on the waiting list for retransplantation. 
b 
2 patients died with severe liver recurrence HCV. 
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Table 5. Univariate and Multivariate Cox Regression of Possible Predictive Factors for Overall 
Intention-To-Treat Survival at 1 year in HCV Liver Recipients. 
Univariate Regression Multivariate Regression 
Parameter HR 95% CI P Value HR 95% CI PValue 
Donor Age (>70) 2.51 1.04 – 6.07 0.04 3.12 1.02 - 3.52 0.046 
Sodium (<145) 0.96 0.92 - 0.99 0.04 
Isosexuality 0.39 0.15 - 0.97 0.04 
Time on List 0.98 0.97 - 0.99 0.02 
UNOS admission: 
1. ICU 8.93 2.60 - 30.62 < 0.001 10.10 2.50 - 41.35 < 0.01 
2. Hospital 3.65 1.09 - 12.12 0.04 
MELD score 1.12 1.05 - 1.19 < 0.001 1.13 1.05 - 1.20 < 0.001 
HIV Coinfection 2.95 1.35 - 6.39 < 0.01 2.65 1.96 - 7.28 0.049 
CI Confidence Interval; UNOS United Network for Organ Sharing; ICU Intensive Care Unit; MELD Model for End-stage Liver Disease; 
HCV/HIV Hepatitis C Virus and Hepatitis Inmunodeficiency Virus. 
Variables significantly associated with survival ITT are highlighted in bold print 
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HCV Included  on Waiting List for  Primary LT 
N = 199 
HCV Monoinfection 
n = 182 (91.5%) 
HCV/HIV Coinfection 
n = 17 (8.5%) 
Other Pathologies 
Died on waiting list 
N = 15 
HCV Monoinfection 
n = 9 
HCV/HIV Coinfection 
n = 6 
Liver Transplant 
N = 161 
HCV Monoinfection 
n = 152 
HCV/HIV Coinfection 
n = 9 
Tracking list 
(monitoring) 
Died 
N = 91 
Alive* 
N = 108 
Intention-to-treat Survival Analysis  
Droppped on waiting list 
N = 14 
HCV Monoinfection 
n = 12 
HCV/HIV Coinfection 
n = 2 
Dec 98 – Jan 15 
Patients Included on Waiting List for Primary OLT 
N = 567 
* Incluied 9 Patients on Waiting List for OLT
Page 21 of 24
John Wiley & Sons, Inc.
Liver Transplantation
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
This article is protected by copyright. All rights reserved.
020
40
60
80
100
0 365 730 1095 1460
HCV Monoinfection HCV/HIV Coinfection
Rank Tests: 
Logrank p value = 0.14 
Wilconxon p value = 0.02 
In
te
n
ti
o
n
-T
o
-T
re
at
  S
u
rv
iv
al
 (
%
) 
Years after the inclusion on the waiting list 
Patients at risk 
HCV Mono 182 123 100 88 78 
HCV/HIV Co 17 9 9 8 5 
   1 2 3 4 
Page 22 of 24
John Wiley & Sons, Inc.
Liver Transplantation
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
This article is protected by copyright. All rights reserved.
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Supplement Table. Characteristics of HCV/HIV Coinfected Patients (ordered by date on the waiting list) 
Baseline Characteristics on waiting list Cause of 
Drop-out 
List 
(cause dead) 
Time 
on 
waiting 
list 
(days) 
Transplant Characteristics ITTA 
Donor Receptor 
Case 
Date 
on waiting 
list 
Age Sex 
Primary 
Indication 
LT 
Genotype 
HCV 
viral 
load 
CD4 
cell 
Count 
HIV 
viral 
load 
Type of 
cART 
(-based) 
Age Sex 
Cause of 
brain 
death 
Type of 
cART 
 (-based) 
HIV 
viral 
load 
Cause 
Retransplant Survival 
Days 
Follow-up 
1 14/05/04 39 Female Cirrhosis 1 4,42E5 480 50 NRTI- EX (infection) 6 Dead 6 
2 24/06/04 41 Male Cirrhosis 2 5,00E5 149 970 NNRTI- LT 28 28 Female Head Trauma NNRTI- 130 Vascular Live 4024 
3 15/04/05 47 Male Cirrhosis 4 5,14E5 184 60 NRTI- EX (others) 12 Dead 12 
4 05/05/06 43 Male Cirrhosis + HCC(a) 1 1,96E6 122 40 PI- LT 37 57 Male CVA PI- < 20 Live 3344 
5 22/06/06 35 Female Cirrhosis other 6,73E5 105 740 PI- IM 208 Live 3296 
6 16/01/07 43 Male Cirrhosis 4 4,47E6 127 450 PI- EX (liver) 7 Dead 7 
7 03/07/07 47 Male Cirrhosis + HCC 3 5,24E7 485 40 PI- LT 207 46 Female CVA PI- < 20 Live 2920 
8 13/07/07 46 Female Cirrhosis 1 2,10E7 180 40 NRTI- LT 132 58 Female CVA NRTI- < 20 Dead(c) 1314 
9 26/03/08 50 Male Cirrhosis 1 6,41E5 124 980 PI- EX (infection) 37 Dead 37 
10 03/07/08 44 Male Cirrhosis 1 4,80E7 166 40 NRTI- LT 33 40 Male Anoxia NRTI- < 20 Dead(c) 1099 
11 12/06/09 48 Male Cirrhosis + HCC 1 5,40E6 226 520 NRTI- DC 96 Dead 347 
12 20/10/09 49 Male Cirrhosis + HCC 4 3,80E7 126 40 PI- LT 39 40 Male CVA PI- < 20 Live 2080 
13 06/04/11 47 Male Cirrhosis 1 4,30E5 673 40 NNRTI- EX (infection) 17 Dead 17 
14 02/12/11 47 Male Cirrhosis 1 2,50E1 120 40 PI- LT 113 71 Female CVA PI- < 20 Live 1307 
15 09/03/12 51 Male Cirrhosis 3 3,10E3 170 40 NNRTI- LT 84 57 Female CVA NNRTI- < 20 Vascular Live 1209 
16 11/02/14 44 Male Cirrhosis 4 3,62E5 110 840 NNRTI- LT 1 38 Female Anoxia NNRTI- < 20 Biliary Dead 280 
17 30/07/14 45 Male Cirrhosis(b) 3 3,47E6 197 27800 NNRTI- EX (liver) 98 Dead 98 
(a) VHB Coinfection; (b) Hepatorenal Transplant; (c) Dead with Disfunctioning Graft (several liver recurrence HCV) 
Cause of drop-oup at list: EX: Exitus waiting list; LT: Liver Transplant; DC: Definitive Contraindication; IM: Improvement 
cART (combined antiretroviral treatment): NRTI: Nucleotido Reverse Transcriptase Inhibitor; NNRTI: No Nucleotido Reverse Transcriptase Inhibitor; PI: Protease Inhibitor 
ITTA: Intention-to-treat Analysis 
Page 24 of 24
John Wiley & Sons, Inc.
Liver Transplantation
48
49
50
51
52
53
54
55
56
57
58
59
60
This article is protected by copyright. All rights reserved.
